Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Cefpodoxime proxetil: adverse event reports

All products with this active ingredient · 3 FDA-approved applications in the Green Book

4,172reports naming this ingredient, 2004–20260.3% of all reports · about 194 a year
344reports, 12 months to March 2026275 in the 12 months before
43.8%classed serious, as reportedof 3,294 reports stating it
10.3%record death or euthanasia, as reported428 reports
95.4%of reports concern dogs0.4% of all dog reports

FDA has received 4,172 adverse event reports in which a drug is recorded with cefpodoxime proxetil as its active ingredient, from October 2004 to March 2026. The Green Book lists 3 FDA-approved applications with this single active ingredient.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 344 reports named it, up 25% from 275 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 194 reports a year and 0.3% of all 1,357,245 reports (0.4% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The signs named most often are vomiting (17.4%), lethargy (13.8%) and anorexia (9.3%). A report can list several signs, so shares add to more than 100%; 1,449 different terms appear across these reports.

95.4% of reports concern dogs. Not every report describes illness: 12.5% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 43.8% were classed as serious, and 10.3% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog1,056 · peak 38
Apr 2021: 12May 2021: 9Jun 2021: 13Jul 2021: 17Aug 2021: 15Sep 2021: 17Oct 2021: 11Nov 2021: 10Dec 2021: 10Jan 2022: 16Feb 2022: 9Mar 2022: 4Apr 2022: 14May 2022: 9Jun 2022: 11Jul 2022: 11Aug 2022: 12Sep 2022: 12Oct 2022: 12Nov 2022: 13Dec 2022: 5Jan 2023: 9Feb 2023: 10Mar 2023: 9Apr 2023: 15May 2023: 8Jun 2023: 8Jul 2023: 16Aug 2023: 16Sep 2023: 14Oct 2023: 16Nov 2023: 19Dec 2023: 17Jan 2024: 17Feb 2024: 28Mar 2024: 12Apr 2024: 19May 2024: 22Jun 2024: 22Jul 2024: 9Aug 2024: 24Sep 2024: 24Oct 2024: 18Nov 2024: 21Dec 2024: 28Jan 2025: 24Feb 2025: 25Mar 2025: 30Apr 2025: 29May 2025: 28Jun 2025: 17Jul 2025: 27Aug 2025: 28Sep 2025: 38Oct 2025: 26Nov 2025: 34Dec 2025: 28Jan 2026: 30Feb 2026: 22Mar 2026: 272022202320242025
Cat18 · peak 2
Jul 2021: 1Sep 2022: 1Dec 2022: 1Sep 2023: 1Nov 2023: 1Dec 2023: 1Feb 2024: 1Apr 2024: 1Jul 2024: 1Mar 2025: 1May 2025: 1Jun 2025: 1Aug 2025: 1Sep 2025: 1Oct 2025: 1Dec 2025: 2Jan 2026: 12022202320242025
Horse0 · peak 1
2022202320242025
Other23 · peak 2
May 2021: 2Jul 2021: 1Sep 2021: 1Mar 2022: 2Apr 2022: 1May 2022: 1Oct 2022: 1Apr 2023: 1Jun 2023: 1Sep 2023: 1Nov 2023: 1Dec 2023: 2Apr 2024: 1Jul 2024: 1Aug 2024: 2Oct 2024: 2May 2025: 1Sep 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

01723442004: 2320042005: 962006: 11320062007: 1412008: 13820082009: 882010: 9520102011: 1132012: 23820122013: 2472014: 26520142015: 2892016: 32220162017: 2922018: 22720182019: 1892020: 16620202021: 1522022: 13520222023: 1662024: 25320242025: 3442026: 802026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of cefpodoxime proxetil reports listing the termall dog reports

  1. Vomiting17.4%727
  2. Lethargy[unusually tired or inactive]13.8%577
  3. Anorexia[not eating]9.3%386
  4. Diarrhoea[diarrhea]7.8%327
  5. Lack of efficacy - NOS[the product did not have the expected effect]7.4%310
  6. Other abnormal test result NOS[abnormal laboratory result, type not specified]6.2%259
  7. Emesis[vomiting]6.1%255
  8. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]6.1%254
  9. Death by euthanasia[the animal was euthanized]5.5%230
  10. Seizure NOS[seizure, type not specified]5.2%215
  11. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]4.7%197
  12. Death4.4%184
  13. Pruritus[itching]4.2%174
  14. Depression[dull, quiet or withdrawn]4.1%170
  15. Polydipsia[drinking more than usual]4.1%169
  16. Lack of efficacy (bacteria) - NOS[the product did not have the expected effect: target not specified]3.9%164
  17. Ataxia[unsteady, uncoordinated movement]3.9%162
  18. Polyuria[passing more urine than usual]3.8%160
  19. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]3.8%157
  20. Fever3.6%149
  21. Anaemia NOS[low red blood cell count]3.5%146
  22. Leucocytosis NOS[high white blood cell count]3.3%136
  23. Behavioural disorder NOS[behaviour change, type not specified]2.9%123
  24. Elevated creatinine[a kidney value above the normal range]2.9%121
  25. Not eating2.9%121
  26. Skin lesion NOS[NOS: not otherwise specified]2.8%118

Top 30 of 1,449 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal21.4%891
Recovered with Sequela1.1%45
Ongoing35.5%1,480
Died6%251
Euthanized4.2%177
Outcome Unknown15.1%630

What kind of report it was

Safety issue84.4%3,522
Lack of expected effectiveness5.5%231
Both safety and lack of expected effectiveness7%292
Manufacturing or product defect3%124
Other0.1%3

Coloured bar: reports naming cefpodoxime proxetil. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog95.4%3,982
Cat2.1%86
Human exposure0.1%6

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year6.7%279
1 to 3 years18.3%764
4 to 7 years28.6%1,193
8 to 11 years27.2%1,133
12 years and over14.1%589
Age not given5.1%214

Weight of the animal

Under 5 kg (11 lb)5.9%248
5 to 9.9 kg (11–22 lb)19.6%817
10 to 24.9 kg (22–55 lb)28.7%1,197
25 to 44.9 kg (55–99 lb)34.3%1,430
45 kg and over (99 lb+)5.2%219
Weight not given6.3%261

Route of administration stated in reports: oral (3,254), subcutaneous (5), topical (4), other (2), parenteral (2), intraocular (1).

In context

MeasureCefpodoxime proxetilAll dog reportsAll reports
Reports4,172985,6751,357,245
Share of that pool's reports naming this drug—0.4%0.3%
Classed serious, of reports stating it43.8%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports102.65563.8
Filed as lack of expected effectiveness (wholly or partly)12.5%—23%
Top term, share of reportsVomiting 17.4%19.7%—

This set accounts for 100% of all reports naming cefpodoxime proxetil, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products containing cefpodoxime proxetil (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
SimplicefCefpodoxime proxetilZoetis Inc.DogsNADA 141-232
Cefpodoxime Proxetil TabletsCefpodoxime proxetilDechra Veterinary Products LLCDogsANADA 200-543
Cefpodoxime Proxetil TabletsCefpodoxime proxetilFelix Pharmaceuticals Pvt. Ltd.DogsANADA 200-815

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about cefpodoxime proxetil reports

How many adverse event reports has FDA received for cefpodoxime proxetil?

4,172 reports record a drug with cefpodoxime proxetil as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 344 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 3 approved applications with this ingredient alone; the reference list on this page names them without any counts.

What signs are reported most often?

vomiting (17.4%), lethargy (13.8%), anorexia (9.3%), diarrhoea (7.8%) and lack of efficacy - NOS (7.4%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (95.4%), cat (2.1%) and human exposure (0.1%). Among single-breed animals the most frequent labels are Labrador Retriever, Golden Retriever, German Shepherd Dog and Shih Tzu; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

344 reports in the 12 months to March 2026, up 25% from 275 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that cefpodoxime proxetil harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of cefpodoxime proxetil?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.